Categories Earnings, Health Care
Bausch Health Companies Inc. (NYSE: BHC): Q4 2019 Earnings Snapshot
— Bausch Health Companies Inc. (NYSE: BHC) reported a loss of $4.30 per share for the fourth quarter of 2019, compared to a loss of $0.98 per share last year, vs. $1.15 per share loss expected.
— Net loss for the quarter was $1.516 billion, compared to a loss of $344 million a year earlier
— December-quarter revenues increased 5% annually to $2.22 billion, vs. $2.2 billion expected
— Revenue of Bausch + Lomb/International, the main business segment, grew 3% annually; Salix segment revenue was up 21%
— Received FDA approval for ARAZLO Lotion for the topical treatment of acne vulgaris in young adults
— Raised capital allocation for research and development by 14% in fiscal 2019, compared to last year
— Expects full-year 2020 revenues to be in the range of $8.65 billion to $8.85 billion
— Looking for adjusted EBITDA in the range of $3.50 billion to $3.65 billion for fiscal 2020
Most Popular
Will the pandemic help or hurt Target (TGT)?
As the coronavirus pandemic rages on, major retailers continue to experience huge demand for food and essential items both in their stores and online. Target Corporation (NYSE: TGT) is one
GameStop (GME) swings to profit in Q4, beats estimates
GameStop Corp. (NYSE: GME) swung to a profit in the fourth quarter of 2019 from a loss last year, helped by lower costs and expenses despite a 28% dip in
Is Skechers’ global footprint strong enough to tide over present crisis?
Footwear maker Skechers USA, Inc. (NYSE: SKX) lost considerable market value in recent weeks and under-performed the industry, amid growing fears that a recession is imminent. The crisis has left